Compare ADMA Biologics Inc (ADMA) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Hilton Hotels Corporation Common Stock trades at $316 (market cap $70.00B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 32.1× ADMA Biologics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HLT | |
|---|---|---|
Market Cap | $2.18B | $70.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $350.22 |
52-Week Low | $7.60 | $256.75 |
Enterprise Value | $2.25B | $83.01B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Hilton Worldwide (HLT) trades at $317.60, down 1.36% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and revenue growth from $12.04B in 2025 to projected $12.5B in 2026. Analyst consensus remains positive with 57% buy ratings and a $352.88 price target, though technical indicators show selling pressure near key resistance at $321.
HLT offers growth potential from travel recovery and pipeline expansion but faces risks from premium valuation (P/E 46.64), rising debt levels (debt-to-asset ratio increased to 73.88% in 2025), and labor disputes. The stock's near-term performance depends on Q3 earnings meeting expectations of $2.38 EPS and managing global demand volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
